Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

Status:

Topic prioritisation

Technology type:

Medicine

Decision:

Not selected

Reason for decision:

Not eligible for Health Technology Evaluation guidance

Rationale:

The NICE-Wide Prioritisation Board met on 03 November 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers concluded that the clear rationale to not evaluate relates to the availability of the existing NHS England commissioning statement for cystic fibrosis CFTR modulators. The board, in agreement with NHS England concluded that an update to this statement to include this patient cohort would be more appropriate. Please see eligibility criteria within the prioritisation manual for further information.

ID number:

12295

Email enquiries

If you have any queries please email topic.selection@nice.org.uk

For further information on how we select topics for development, please see our page about topic prioritisation